Array Biopharma files new-drug applications, stock price climbs
BOULDER — Cancer-research firm Array Biopharma Inc. (Nasdaq: ARRY) filed new-drug applications with the U.S. Food and Drug Administration.
The drug applications are for the combined use of 45 milligrams of binimetinib twice a day with 450 milligrams of encroafenib once a day for the treatment of patients with advanced or metastatic melanoma.
Array filed the applications after positive results from its phase three Columbus study. That study found that patients who use that combination of drugs have a survival rate without progression of the cancer that is longer than other drugs in use.
SPONSORED CONTENT
Business Cares: March 2024
WomenGive, a program of United Way of Larimer County, was started in Larimer County in 2006 as an opportunity for women in our community to come together to help other women.
Array’s stock price was $8.85 per share at the time of publication, a 15-cent increase from when the market closed on July 3, prior to the news of the drug applications.
BOULDER — Cancer-research firm Array Biopharma Inc. (Nasdaq: ARRY) filed new-drug applications with the U.S. Food and Drug Administration.
The drug applications are for the combined use of 45 milligrams of binimetinib twice a day with 450 milligrams of encroafenib once a day for the treatment of patients with advanced or metastatic melanoma.
Array filed the applications after positive results from its phase three Columbus study. That study found that patients who use that combination of drugs have a survival rate without progression of the cancer that is longer than other drugs in use.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!